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Abstract
Background: The rise in tuberculosis (TB) incidence following generalized HIV epidemics can overwhelm TB control
programmes in resource-limited settings, sometimes accompanied by rising rates of drug resistance. This has led to claims
that DOTS-based TB control has failed in such settings. However, few studies have described the effect of a sustained and
well-supported DOTS programme on TB incidence and drug resistance over a long period. We present long-term trends in
incidence and drug resistance in rural Malawi.
Methods: Karonga District in northern Malawi has an adult HIV prevalence of ,10%. A research group, the Karonga
Prevention Study, collaborates with the National Tuberculosis Programme to support core TB control activities.
Bacteriological, demographic and clinical (including HIV status) information from all patients starting TB treatment in the
District have been recorded since 1988. During that period isolates from each culture-positive TB patient were exported for
drug sensitivity testing. Antiretroviral therapy (ART) has been widely available since 2005.
Results: Incidence of new smear-positive adult TB peaked at 124/100,000/year in the mid-90s, but has since fallen to 87/
100,000/year. Drug sensitivity information was available for 95% (3132/3307) of all culture-positive cases. Initial resistance to
isoniazid was around 6% with no evidence of an increase. Fewer than 1% of episodes involved a multi-drug resistant strain.
Discussion: In this setting with a generalised HIV epidemic and medium TB burden, a well-supported DOTS programme
enhanced by routine culture and drug sensitivity testing may well have reduced TB incidence and maintained drug
resistance at low levels.
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Introduction
The HIV epidemic caused a dramatic increase in tuberculosis
(TB) incidence in sub-Saharan countries. [1] In South Africa the
HIV-driven rise in TB incidence was accompanied by escalating
rates of TB drug resistance. [2] However, few data are available
from other sub Saharan countries [3,4], especially on trends in
drug resistance. [5–7].
The current debate around TB control is focusing on the rapid
scale-up of improved, but costly, new diagnostics as a measure
essential to TB control in HIV endemic settings. [8–12]
Unfortunately, infrastructural and financial restrictions make the
implementation of currently available tests, such as GeneXpert,
highly unlikely at the peripheral level in low income settings. [13]
TB control programmes in these areas, where the majority of
people at risk of TB live, may require an alternative approach,
which could include strengthening existing DOTS-based systems.
WHO’s 2010 global report showed signs that overall TB
incidence rates are beginning to fall in the African region outside
South Africa [14], and that, despite their limited resources, the
standard DOTS, smear-microscopy based programmes in the area
are starting to control TB. Cross sectional surveys also suggest that
drug resistance levels are relatively low in much of Africa. [3–6].
We report long-term trends in TB incidence and drug resistance
in the context of a well-supported TB programme in Karonga
District, a rural district in northern Malawi [15], where an
effective ART programme is in place. [16] Previous reports from
this area showed a HIV-induced rise of TB incidence during the
1990s, [17] and stable drug resistance over that period. [18–20]
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We now present TB incidence and drug resistance trends during a
further decade of TB control.
Methods
Ethics Statement
Informed consent was sought from all participants, including
separate counselling and consent for HIV testing. In the earlier
years of the study, data were collected in the context of providing a
clinical and audit service for the TB control programme and
consent was verbal, in line with norms of operational research at
the time. A record of whether individual TB patients were willing
or unwilling to participate in data collection or to accept HIV
testing and counselling, was held in hand-written TB patient
registers owned by the National TB programme. Those patients
who also participated in trials conducted during that period, were
asked for written consent by the Karonga Prevention Study (KPS).
Since 2001, all TB patients have been asked for written consent for
routine procedures, if undertaken by KPS rather than government
staff. All written consent forms are stored on site at the KPS
headquarters in Chilumba, Malawi. Ethical approval for the study,
including consent procedures at each time point, was received
from the London School of Hygiene & Tropical Medicine and the
Malawian National Health and Sciences Research Committee
(current approval numbers LSHTM #5067 and NHSRC #424).
Study Setting
Karonga District covers 3355 km2 and its current total
population is estimated around 300,000. [21] Adult HIV
prevalence peaked at 12% in the mid-1990s, and is currently
stable around 10% ([22] & unpublished data). The first ART clinic
opened in 2005 [23] and as of June 2011, over 5000 individuals
were receiving ART from 6 clinics. In collaboration with the
National Tuberculosis Programme (NTP), a research group, the
Karonga Prevention Study (KPS) has been supporting core TB
programme activities and conducting TB epidemiological studies
of TB in Karonga District since 1986. [15].
Patients and Case Finding
Case finding procedures have changed over time for study
purposes, and are summarized in table 1. In 1986–89 a total
population survey was conducted as the recruitment phase of a
vaccine trial of repeat BCG and killed M.leprae. [24,25] Everyone
seen was asked about cough and examined for lymphadenopathy.
From the end of the survey to 2007 KPS field staff were based
in all health centres, where one of their functions was to take
sputum samples from individuals presenting with chronic cough or
lymphadenopathy. Three sputa were collected following a spot-
morning-spot schedule. [26] If the individual did not present at the
clinic the next day, the field worker would collect sputa at the
household. Since 2007, field workers have only been present one
morning a week at the small health centres (their work is now
covered by local health staff). KPS still has a continuous presence
at the three main clinics.
From 1997–99 a study of lymph node TB increased the number
of biopsies and fine needle aspirates taken from suspected cases.
[27] An immunological study, started in 2008, recruited patients
from the general ward in the district hospital. These patients were
screened for TB as part of the protocol, regardless of symptoms,
thus potentially intensifying case finding on the ward.
Participants in other community-based KPS studies in the
District are also asked about persistent cough. [15] This screening
has a low yield, suggesting that case detection through the routine
measures is good.
Laboratory Diagnosis
Samples are transported to the KPS laboratory in the south of
the district. All samples are investigated for mycobacteria using
smear microscopy, initially with Ziehl-Neelsen staining only, but
since 1996 all smears have been screened using auramine-stained
fluorescence microscopy, with Ziehl-Neelsen confirmation of
positives.
Results from the KPS laboratory are reported back to the field
worker who took the samples and to the NTP. When positive, the
result is delivered to the household if the individual does not return
to the health centre to collect it, and the patient is referred for TB
treatment. If a person does not present to the clinic, they are again
visited at home to encourage them to come for treatment.
Specimens are cultured on Lowenstein-Jensen media for the
isolation of Mycobacterium species. Patients are started on
treatment if a culture growth suggests M.tuberculosis.
Species confirmation and drug sensitivity testing are done at the
HPA National Mycobacterium Reference Laboratory in the
United Kingdom. Samples are sent in batches to minimize
international transport costs. Final results, therefore, typically
arrive at least 12 weeks after sputum is first taken and submitted,
but can sometimes take much longer. Drug resistance is tested
using the ratio method. [28] Until 2001, all first line drugs were
tested and if resistance was found, further sensitivity testing for
second line drugs was carried out. From 2001 onwards, samples
were initially tested for resistance to isoniazid and rifampicin only,
with further testing if resistance was seen to either of these drugs.
All isolates from culture-positive patients from 1996 to 2008 have
undergone molecular typing using IS6110 RFLP. [29–30].
Treatment and Follow-up
Until 2004, KPS acted on behalf of the NTP in collaboration
with the District TB officer to register and distribute treatment to
patients. Since 2004, this task has been managed by the NTP.
Since 1988 all TB patients have been offered HIV testing by KPS
staff and since 2005 they have been referred for ART screening
when HIV-positive. Eligibility for ART relied mainly on clinical
staging as WHO stage 3 or 4; CD4 was not widely available. For
those with access to CD4 testing, the level at which they were
eligible for ART increased from 200 to 250 in 2007, and to 350 in
2011.
TB treatment regimens have followed NTP guidelines through-
out the study period, and currently the standard DOTS treatment
is given to all patients (see table 2). [31] Rifampicin has been part
of the intensive treatment phase since 1984 and has been given
throughout treatment since 2007. [31].
Second line anti-TB drugs were not available in Malawi until
2007. [31] Initially, the NTP recommended use of isoniazid and
ethambutol for patients with multidrug resistant (MDR) TB. Since
2007, MDR-TB has been treated with six months of pyrazin-
amide, cycloserine, ethionamide, ofloxacin and an injection of
capreomycin, followed by eighteen months of the same drugs
without capreomycin. These drugs have to be requested by the
District TB coordinator directly from central medical stores
following a laboratory confirmation of MDR TB. In this setting
patients are often close to completion of first line treatment by the
time MDR TB is confirmed due to the time taken for culture and
the batching of cultures for international transportation.
The procurement, distribution and dispensing of anti-tubercu-
losis drugs in Malawi are strictly regulated, with sole authority
given to the NTP. Private health care providers can diagnose TB,
but have to register their patients with the National Programme
before they are given the necessary anti-tuberculosis drugs.
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For smear-positive TB cases KPS collects samples at the end of
the intensive treatment phase (2 months for standard treatment)
and 1 month before the end of treatment, to confirm smear
conversion. Review samples are collected at the household if
necessary. All smear-positive review sputa are cultured as are all
end of treatment specimens.
Data Collection
All consenting patients starting TB treatment were interviewed
by KPS staff to record information on clinical symptoms, socio-
demographic background information and history of TB. Infor-
mation on previous TB treatment was recorded from the KPS
database and self-reports by the patient. If a patient defaulted or
died before completion of treatment, they were traced or
information was collected from reliable informants. From 1988
HIV testing has been offered by trained KPS field staff at
diagnosis, and from 2005 onwards self-reports of ART usage have
also been recorded. All data were double entered and verified.
Analysis
TB episodes were classified as pulmonary or extra-pulmonary.
Patients with mixed pulmonary and extra-pulmonary disease were
classified as pulmonary. For the main incidence analysis we
included all new episodes of smear-positive pulmonary TB in
adults (age 15+) from 1988 onwards, in line with our previous
report from this setting, because case ascertainment and diagnosis
was most constant over time for this group. [17] Adult population
denominators for Karonga District were acquired from our whole
population survey data for the 1980s, and from national censuses
from 1998 and 2008, assuming exponential growth between each
Table 2. TB treatment regimen in Malawi during the study period.
Patient Category Period and Regimen
1984–1995 1996–2000 2001–2006 2007 to present
New TB patients
Adult* smear-positive pulmonary
including military TB; Extra-pulmonary
TB of the spine and pericardium
2SRHZ/6HT3 2SRHZ/6HE 0.5RHZE/1.5R3H3Z3E3/6EH 2RHZE/4RH
Adult smear-negative TB and
other extra-pulmonary TB not
included above
1SEH/11HT3 1SEH/11HE 0.5RHZE/1.5R3H3Z3E3/6EH 2RHZE/4RH
Children* 2SRHZ/6HT3 5R3H3Z3/6EH* 0.5(RH)HZE/1.5(RH)3H3Z3E3/6EH* 2RHZ/4RH*
TB meningitis 2SRHZ/7RH 2SRHZ/7RH 2SRHZ/7RH 2SRHZ/7RH
Previously treated for TB
Recurrent TB, TB treatment failures
and Defaulters
2SRHZE/1RHZE/5HT3 2SRHZE/1HRZE/5R3H3Z3E3 2SRHZE/1RHZE/5R3H3Z3E3 2SRHZE/1RHZE/5RHE
*Adult = 15 years or older, child = less than 15 years old.
S = streptomycin; R = rifampcin; H = isoniazid; Z =pyrazinamide; T = thiacetazone; E = ethambutol. Large numbers indicate duration in months. All drugs taken daily,
unless subscript indicates alternative number of doses a week.
doi:10.1371/journal.pone.0058192.t002
Figure 1. Incidence of new smear-positive pulmonary TB in Karonga District in adults. Error bars indicate 95% confidence intervals.
doi:10.1371/journal.pone.0058192.g001
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census. [21] As many TB patients are started on treatment without
any laboratory confirmation but based on X-ray or clinical
indication, the incidence analyses were repeated with all new
patients.
The drug resistance analysis included all culture-positive TB
patients (including ,15 year olds) who had drug sensitivity
information available since 1988. ‘‘Initial’’ resistance was defined
as resistance to an antituberculous drug in a confirmed M.tuber-
culosis isolate from a sputum sample taken before, or within the first
month, of treatment from a patient with no previous treatment for
TB. A separate analysis was done for those who had previously
been treated (sometimes called ‘‘acquired’’ resistance). [28] Multi-
drug resistance (MDR) was defined as resistance to both isoniazid
and rifampicin.
We defined a patient as having a ‘‘clustered’’ strain if the strain
had an RFLP pattern identical to that seen in another patient in
the previous 5 years. Other strains were classified as unique.
Logistic regression was used to investigate associations between
key variables and the presence of initial resistance to INH. TB
cases with confirmed MDR were investigated in detail.
Table 4. Association between patients’ characteristics and resistance to INH.
Initial resistancea Recurrent TB
Background Characteristics % resistance (n/N) OR (95% CI)e % resistance (n/N) OR (95% CI)e
Sex
Female 5.1 (69/1350) Ref 13.8 (21/152) Ref
Male 6.6 (85/1293) 1.29 (0.93–1.79) 17.3 (28/162) 1.26 (0.67–2.37)
Age
,15 10.2 (6/59) 2.39 (0.97–5.94) 20.0 (1/5) 1.21 (0.12–12.7)
15–24 5.9 (22/372) 1.37 (0.80–2.36) 9.5 (2/21) 0.56 (0.12–2.70)
25–34 4.2 (39/929) Ref 14.8 (17/115) Ref
35–44 7.8 (49/632) 1.89 (1.23–2.93) 16.5 (13/79) 1.04 (0.46–2.35)
$45 5.8 (38/651) 1.38 (0.87–2.19) 17.0 (16/94) 1.14 (0.53–2.46)
TB Type
Pulmonaryb 5.9 (147/2509) Ref 16.0 (49/306) –
Extra-pulmonary only 5.2 (7/134) 0.92 (0.42–2.04) 0 (0/8) –
Sputum Status
smear-negative 5.9 (41/690) Ref 8.7 (6/69) Ref
smear-positive 5.8 (113/1953) 0.99 (0.68–1.44) 17.6 (43/245) 2.29 (0.91–5.75)
HIV-negative 5.8 (45/773) Ref 21.7 (21/97) Ref
HIV-positive 6.0 (62/1027) 1.09 (0.73–1.64) 10.4 (16/154) 0.54 (0.25–1.18)
HIV-pos – not on ARTc 7.1 (7/99) Ref 11.1 (1/9) Ref
HIV-pos – on ARTc 11.4 (8/70) 1.70 (0.59–4.92) 5.0 (1/20) 0.42 (0.02–7.59)
Clustered with other case in the pastd
Unique RFLP fingerprint 5.9 (32/544) Ref 11.5 (6/52) Ref
Clustered RFLP fingerprint 6.3 (62/982) 1.11 (0.70–1.75) 12.2 (16/131) 1.01 (0.36–2.83)
a‘Initial resistance’ defined as resistance found in sample from patient with less than 1 month of TB treatment and experiencing their first TB episode.
bthis includes mixed pulmonary and extra-pulmonary TB (n = 87 for initial, n = 7 for recurrences);
conly for HIV-positive episodes occurring from 2005 onwards;
dN is lower because RFLP not available for all cases;
eadjusted for period; Ref = reference category.
doi:10.1371/journal.pone.0058192.t004
Table 3. Anti-Tuberculosis drug resistance trends, 1988–
2010.
Initial % (n/N) Recurrent TB
Year INH
(MDR)
INH+RIF INH
(MDR)
INH+RIF
1988–1990 8.9 (22/246) 0.4 (1/246) 34.8 (8/23) 0 (0/23)
1991–1993 4.5 (12/267) 0 (0/267) 20.0 (5/25) 0 (0/25)
1994–1996 5.1 (14/277) 0.4 (1/277) 17.2 (5/29) 3.5 (1/29)
1997–1999 6.0 (33/555) 0.9 (5/555) 9.0 (6/67) 0 (0/67)
2000–2002 4.4 (20/457) 0.4 (2/457) 15.7 (8/51) 0 (0/51)
2003–2005 6.8 (26/382) 1.1 (4/382) 14.8 (8/54) 0 (0/54)
2006–2008 5.1 (16/317) 0.3 (1/317) 15.9 (7/44) 0 (0/44)
2009–2010 7.8 (11/142) 0.7 (1/142) 9.5 (2/21) 9.5 (2/21)a
Total 5.8 (154/2643) 0.6 (15/2643) 15.6 (49/314) 0.9 (3/314)
n = number resistant, N = total number tested, INH= isoniazis, RIF = Rifampcin,
MDR=Multi-drug resistance.
aconfidence interval for estimate = 0–23%.
doi:10.1371/journal.pone.0058192.t003
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Results
Incidence
Between January 1988 and June 2011 6172 episodes of TB were
registered in adults, of which 3748 (61%) had some form of
laboratory confirmation (at least 1 positive smear or culture,
excluding single scanty positive smears, or positive histology),
which means 39% of patients were started on empirical TB
treatment based on X-ray and/or clinical symptoms alone.
After excluding recurrent episodes (n = 419), episodes with
extrapulmonary involvement only (n = 146) and smear-negative
TB (n= 591), we included 2592 episodes of new smear-positive
pulmonary TB in the analysis. Figure 1 illustrates the trends in TB
incidence, with the HIV-induced peak in the mid 909s. Since then
incidence has declined steeply, and has stabilized at a level below
that of 1988, the early years of the HIV-epidemic. [22].
A similar trend was seen when all new adult cases were
included, a peak around 280/100,000/year in the 1990’s, but a
steady decline to 136/100,000/year recently, well below the 206/
100,000/year recorded in 1988–1990. The 33 cases (23 new
smear-positives) that were identified during the immunological
survey which started in 2008 are included in the analyses.
The proportion of all TB episodes that were due to recurrence
(i.e. a new episode after treatment was completed) rose from 8% in
88–90 to 13% in 00–02, but has remained stable since.
Drug Resistance
Drug sensitivity information was available for a total of 3132/
3307 (95%) of culture-positive episodes (including 71 from ,15
year olds) that occurred between January 1988 and December
2010. Of these, 2643 had information on initial resistance status
(i.e. first episode of TB for that patient and drug resistance test
information available from a sample collected before one month of
treatment was completed).
The proportions of TB cases with initial isoniazid or multi-drug
resistance are shown in table 3. Overall fewer than 6% (5.8%,
154/2643) of cases had initial isoniazid resistance and 0.6% (15/
2643) had initial MDR resistance. Resistance to isoniazid was
higher 15.6% (49/314) in cases that had been treated for TB
before, and acquired MDR was 0.9% (3/314). There was no
evidence of any increase in drug resistance over time.
Table 4 shows the association between patient characteristics
and initial or acquired resistance to isoniazid. The proportions
with initial INH resistance were similar in males and females, in
those with different types of TB and by HIV/ART status. There
was no consistent trend with age, with the lowest resistance levels
in the age group 25–34. There was no evidence of an association
between drug resistance and whether the RFLP-fingerprint had
been previously seen in that population (i.e. was clustered) or not.
Details of the 18 patients with MDR are shown in table 5. MDR
TB was seen at low levels throughout the study period, over a wide
age range, and in HIV-positive and HIV-negative individuals.
Case fatality rates were high (46.7% (7/15) with initial MDR,
compared to 21.8% (720/3307) of all culture positive cases). RFLP
results were available for 12 patients with MDR TB; four patients
diagnosed with initial MDR TB between 1994 and 2003 shared a
common strain, kps_43. This was only found in two other patients;
a 1995 patient with initial resistance to INH (and streptomycin),
and a patient in 1999 with a fully sensitive strain. There were no
known epidemiological links between the 4 MDR patients. The
two patients with MDR TB due to strain kps_12 were husband
and wife. Strain kps_12 is one of the more common strains in the
area [32], and initial INH resistance was found in 34% (9/41) of
all episodes with this strain.
Discussion
Our data show that with good support, TB control in Karonga
District has kept drug resistance levels low, including in recurrent
cases. Furthermore, despite an increase in TB incidence following
the rise in HIV prevalence, and 60% of the TB cases being HIV-
positive, TB incidence levels are now lower than those seen in the
early years of the HIV epidemic. [17].
Our results are in line with national reports from the region
which mostly show declining trends in TB incidence in recent
years. [14] Similar levels of drug resistance were seen in several
cross-sectional surveys in the region (Zambia, Uganda and
Botswana) in the context of generalised HIV epidemics and
standard smear-microscopy based DOTS programmes. [3–6] As
in these studies, no evidence was found of an association between
drug resistance and HIV status or ART use, although the numbers
on ART are small in our study.
The research activities in Karonga District may have improved
TB control, but we believe this is largely because we were able to
ensure basic activities were carried out correctly rather than
because of any high tech or costly interventions. Our system of
having staff at peripheral health clinics is a form of enhanced case
finding that could be replicated by providing basic training of local
staff. Other, population-based, studies at KPS yield very few TB
cases, suggesting that our clinic-based case detection is at
acceptable levels. The immunological study may have increased
case-finding in the hospital, although the proportion of all TB
cases that was found on the general ward was similar in the 1997–
2007 and 2008–2009 period (12.9% versus 15.7%, p= 0.3) It is
also likely that a proportion of the cases identified through this
sub-study would have been found through regular passive case
finding at a later date, albeit more spread out over time.
The culture confirmation for all individuals suspected of having
TB, and speciation plus drug sensitivity for all culture-positive
cases would have had limited impact on clinical care, due to the
very low levels of drug resistance in our region and intensive
microscopic and clinical surveillance strategy, and are not essential
for achieving the results. As an indication, approximately 5% of
smear-negative culture positive cases were commenced on TB
treatment after a positive culture report was available (unpublished
data), the overwhelming majority having already started TB
treatment on clinical suspicion prior to receiving the culture result.
Thus, this is unlikely to have had a major impact on TB incidence
trends.
Our sputum collecting protocol for TB suspects (three samples
over two days, ‘spot-morning-spot’ [26]) is labour-intensive and
maintained for study reasons. Alternative approaches, such as
taking two spot-sputa on the same day, can be effective while
reducing the laboratory and health staff workload. Our strategy of
following up patients at their household if they failed to return to
the clinic was also likely to be an important factor in the overall
success [26,33].
Throughout, we have used treatment as determined by the
NTP. In the earlier years we supported treatment, but there has
been no rise in resistance or incidence following the transfer of
treatment services back to the NTP. Rifampicin has been in use in
the intensive phase throughout and has been part of the
continuation phase since 2007, but initial MDR rates have
remained low, suggesting continued absence of onward MDR
transmission. The proportion of episodes with resistance was
similar in clustered and unclustered strains, suggesting no overall
effects on transmissibility. It will be important to continue to
monitor rifampicin resistance now that it is used throughout
treatment, increasing selective pressure.
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These data provide a comprehensive picture of TB control in a
challenging setting. The reduction in incidence occurred at a time
when HIV prevalence appeared to be stable [22] and before
widespread use of ART. Although it could be explained by lower
case detection, there is no evidence for this. Restricting the analysis
to smear positive cases, for whom procedures were similar over
time, should minimize this potential bias.
In Karonga District, the decline in TB incidence seems to have
halted. The reasons for this are unclear. It is not explained by the
extra cases identified through screening on the general wards. To
bring incidence down further, more intensive screening may be
needed, in high risk populations (e.g. ART clinics) or in the
community. Such studies are underway in Karonga District.
Conclusion and Recommendations
Our results re-emphasize the need for doing the ‘simple things’
well. Improving TB control should include strengthening the
existing, sputum smear based DOTS infrastructure, as well as
support of ART programmes, which remain the cornerstones of
cost-effective, equitable and sustainable TB control in many
resource-limited settings. This applies in particular for peripheral
rural areas, where drug resistance levels are probably low. For
these areas, low-tech and low-cost improvements to TB care would
be appropriate.
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